Johnson & Johnson (J&J) is betting on differentiated treatments for eye conditions such as wet age-related macular degeneration (AMD), spending up to $3.3bn to acquire ophthalmology drug developer Ollin Biosciences.
J&J is paying $2.2bn upfront for the biotech, with regulatory and commercial milestone payments totalling a further $1.125bn.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Ollin’s lead candidate is OLN324, an investigational bispecific antibody designed to target two key pathways in retinal diseases, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), that is in Phase III trials. It is in development for wet AMD and diabetic macular oedema (DME) – two common causes of vision loss.
Currently, the eye disease market is dominated by Regeneron/Bayer’s Eylea (aflibercept) franchise and Roche’s Vabysmo (faricimab). Both products are anti-vascular endothelial growth factor (anti-VEGF) inhibitors and are blockbuster drugs. Eylea is approaching the end of major patent protections, and biosimilars are already entering the market.
Ollin has already touted OLN324’s superior efficacy to Vabysmo. In a Phase Ib head-to-head study, Ollin’s asset showed better visual acuity gains and retinal drying, among other clinical outcomes. OLN324 is also moving into Phase III studies for both wet AMD and DME. J&J said it would advance the asset and build on Ollin’s science.
“The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients,” said J&J’s ophthalmology disease area stronghold leader, Kip Connor.
Announced with the Ollin deal was a separate funding agreement with Blackstone Life Sciences. The private equity firm will pay $750m to J&J to fully fund Phase III development of OLN324. In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments as well as single-digit royalties.
The deal for Ollin marks the latest deal that J&J has conducted in the second half of the year. In June, it agreed to acquire Firefly Bio for $1bn to bolster its oncology pipeline, while investment in Sail Biomedicines a month later saw J&J secure acquisition rights for the CAR-T specialist.
